There is no approved vaccine for breast cancer. The only cancer-preventing vaccines currently approved by the FDA target cervical cancer (HPV vaccine) and liver cancer (hepatitis B vaccine), both caused by viruses. Breast cancer isn’t driven by a single virus, which makes developing a vaccine far more complex. However, several promising candidates are now in clinical trials, and one preventive vaccine could enter larger testing by late 2026.
Why a Breast Cancer Vaccine Is Harder to Make
Traditional vaccines work by training your immune system to recognize a virus before it causes disease. Cervical and liver cancer vaccines follow this model because those cancers are triggered by specific viral infections. Breast cancer, by contrast, arises from your own cells mutating and growing out of control. Your immune system is designed to leave your own cells alone, so getting it to attack a tumor without harming healthy tissue is a much trickier problem.
Researchers have found a workaround: targeting proteins that appear on breast cancer cells but are mostly absent from normal adult tissue. If a vaccine can teach your immune system to recognize one of these proteins, it could destroy cancer cells early, before a tumor ever takes hold, or mop up stray cancer cells after treatment to prevent recurrence.
The Preventive Vaccine Furthest Along
The most advanced preventive breast cancer vaccine targets a protein called alpha-lactalbumin. This protein is normally produced in breast tissue only during lactation. Once breastfeeding ends, healthy breast tissue stops making it. But roughly 70% of triple-negative breast cancers, one of the most aggressive forms of the disease, overexpress alpha-lactalbumin. The idea is straightforward: vaccinate against a protein your body no longer needs, and your immune system will attack any future tumor that produces it.
Cleveland Clinic researchers completed a Phase 1 trial with 35 patients in three groups: women who had finished treatment for early-stage triple-negative breast cancer, women with genetic mutations who opted for preventive mastectomy, and women with residual disease after surgery and chemotherapy. The vaccine triggered an immune response in 74% of all participants. Side effects were mild, limited to injection site reactions classified as the lowest severity grade. The study sponsor, Anixa Biosciences, plans to open a Phase 2 trial in late 2026 to test whether the vaccine actually prevents cancer recurrence, not just whether it activates the immune system.
Phase 1 trials are designed to check safety and immune response, not to prove a vaccine works. Phase 2 will begin answering whether immunized women develop fewer recurrences compared to those who don’t receive the vaccine. A Phase 3 trial and FDA approval, if everything goes well, would still be years away.
Therapeutic Vaccines That Treat Existing Cancer
Separate from prevention, therapeutic vaccines aim to help patients who already have breast cancer. These vaccines don’t stop you from getting cancer. Instead, they train your immune system to fight tumors that are already present or to prevent recurrence after initial treatment. Think of them less like a flu shot and more like a targeted boost to your body’s natural defenses.
One candidate called GP2 targets HER2-positive breast cancer, a subtype where cancer cells overproduce a growth-promoting protein. GP2 is currently in a Phase 3 trial, the final stage before potential FDA approval. The study is measuring how long vaccinated patients remain free of invasive breast cancer compared to a placebo group, with an interim analysis planned after a median of four years of follow-up. Results have not yet been reported.
Another therapeutic approach uses a DNA-based vaccine targeting the internal portion of the HER2 protein. In a Phase 1 trial of 66 patients with advanced HER2-positive breast cancer, the most common side effects were injection site reactions (82% of patients), flu-like symptoms (33%), and fatigue (36%). Nearly all side effects were mild, with 98% of patients experiencing only the lowest severity grade.
How mRNA Technology Fits In
The same mRNA platform behind COVID-19 vaccines is being adapted for breast cancer. Instead of encoding a viral spike protein, these vaccines encode tumor-associated proteins, teaching your immune cells to recognize and kill cancer cells that display those proteins. Several mRNA breast cancer vaccines are in early clinical trials.
One approach delivers mRNA encoding a protein called MUC1, which the National Cancer Institute ranked as the second most promising tumor-associated target. In preclinical studies, mRNA nanoparticles traveled to lymph nodes, where they activated immune cells called dendritic cells. Those dendritic cells then trained specialized killer T cells to hunt down triple-negative breast cancer cells. Unlike some older vaccine strategies that primarily generate antibodies, mRNA vaccines are particularly effective at triggering this T cell response, which is considered critical for destroying solid tumors.
Other mRNA trials are targeting HER2 or using a personalized approach, creating vaccines based on the unique mutations found in an individual patient’s tumor. These neoantigen vaccines are still in Phase 1 and Phase 2 trials, so it will be some time before their effectiveness is clear.
What This Means for You Now
No breast cancer vaccine is available outside of clinical trials today. If you’re at high risk for breast cancer, particularly triple-negative breast cancer, clinical trials may be an option. The alpha-lactalbumin vaccine trial at Cleveland Clinic enrolled women who had completed treatment for early-stage triple-negative breast cancer as well as women carrying genetic mutations that increase breast cancer risk. Future Phase 2 enrollment criteria have not yet been finalized.
For HER2-positive breast cancer, the GP2 Phase 3 trial is actively studying whether vaccination after standard treatment can prevent recurrence. Trial listings on ClinicalTrials.gov provide the most current information on enrollment status and eligibility for both vaccines.
The timeline from here is measured in years, not months. Even the most optimistic projections place the first potential FDA approval well into the late 2020s at the earliest, and only if larger trials confirm the safety and effectiveness signals seen so far. The early results are genuinely encouraging, with strong immune responses and manageable side effects, but the hardest question remains unanswered: do these immune responses actually translate into fewer cancers and longer survival?